FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023

Source: iQoncept / Shutterstock

Homology Medicines (NASDAQ:FIXX) just reported results for the fourth quarter of 2023.

  • Homology Medicines reported earnings per share of -27 cents. This was above the analyst estimate for EPS of -30 cents.
  • The company did not report any revenue for the quarter.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].


Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/fixx-stock-earnings-homology-medicines-for-q4-of-2023/.

©2024 InvestorPlace Media, LLC

Source link

Share with your friends!

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest stocks updates
straight to your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.